Jump to content
PayMap
  • entries
    43
  • comments
    9
  • views
    518

About this blog

  • The related invention patents about artemisinin and their translations in Chinese and English.
  • 关于青蒿素的相关发明专利及中英文翻译。
  • Short Link: gettr.ink/2CZ5TP

Entries in this blog

Artemisinin Patent｜青蒿素专利

青蒿素触发人类Ishikawa子宫内膜癌细胞的G1细胞周期停滞并通过破坏NF-kB转录信号通路抑制细胞周期依赖性激酶4（CDK4）的启动子活性和表达｜Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits Cyclin Dependent Kinase-4 promoter activity and expression by disrupting NF-kB t

本文短链接： https://gettr.ink/FNyAe4 Sourse: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172338/ 青蒿素触发人类Ishikawa子宫内膜癌细胞的G1细胞周期停滞并通过破坏NF-kB转录信号通路抑制细胞周期依赖性激酶4（CDK4）的启动子活性和表达 作者：Kalvin Q. Tran, Antony S. Tin, and Gary L. Firestone 加州大学伯克利分校分子与细胞生物学系和癌症研究实验室，伯克利，加利福尼亚州，94720-3200 摘要 目前关于青蒿素（一种源自青蒿的天然抗疟药物）在人体子宫内膜癌细胞中的抗增殖作用知之甚少。青蒿素在培养的人类Ishikawa子宫内膜癌细胞中引发了G1细胞周期停滞，并下调了CDK2和CDK4的转录和蛋白水平。CDK4启动子-荧光素酶报告基因的分析表明，青蒿素对CDK4基因表达的抑制与CDK4启动子活性的丧失有关。染色质免疫沉淀显示青蒿素抑制了NF-κB亚基p65和p50与Ishikawa细胞
Artemisinin Patent｜青蒿素专利

抗肿瘤活性的青蒿素及其衍生物：从一种广为人知的抗疟药到一种潜在的抗癌药物 Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug

本文章短链接：https://gettr.ink/r35txQ Sourse ：https://onlinelibrary.wiley.com/doi/epdf/10.1155/2012/247597   抗肿瘤活性的青蒿素及其衍生物：从一种广为人知的抗疟药到一种潜在的抗癌药物 Hindawi Publishing Corporation Journal of Biomedicine and Biotechnology 2012年卷，文章ID 247597，18页 doi:10.1155/2012/247597 综述文章 抗肿瘤活性的青蒿素及其衍生物：从一种广为人知的抗疟药到一种潜在的抗癌药物 Maria P. Crespo-Ortiz1 和 Ming Q. Wei2 1 圣地亚哥德卡利大学基础与健康科学学院生物医学系，哥伦比亚卡利Pampalinda校区 2 格里菲斯大学健康研究所及医学院分子与基因治疗系，澳大利亚昆士兰州南港，黄金海岸校区 通讯地址：Maria P. Cresp
Artemisinin Patent｜青蒿素专利

Novel applications of artemisinin ingredients or composition of artemisinin ingredients in skin care|青蒿素类成分或其组合物在皮肤护理中的新应用

Short Link : https://gettr.ink/APp5Ab The invention relates to novel applications of the defined artemisinin ingredients or a composition of the artemisinin ingredients, namely, the novel applications in the skin care field of mammals. According to the novel applications, the bad state of the skin of the mammals is eliminated or alleviated so that the healthy and beauty of the skin are enhanced through the means of regulating the keratinization disorder, inhibiting hyperpigmentation, resist
Artemisinin Patent｜青蒿素专利

Application of the Artesunate as immunologic adjuvant in preparation rabies vacciness|青蒿琥酯作为免疫佐剂在制备狂犬病疫苗中的应用

The present invention provides application of the Artesunate as immunologic adjuvant in preparation rabies vacciness, and present invention firstly provides artemisinin derivative Artesunate (ART) is used as rabies vacciness adjuvant.The present invention passes through experimental studies have found that artemisinin derivative Artesunate (ART) is as rabies vacciness adjuvant can significantly increase its immunogenicity, can be used as new semple type rabies vaccine candidate adjuvant.The Arte
Artemisinin Patent｜青蒿素专利

Effects and application of artemisinin and its derivative in inhibition of platelet-derived growth factor receptor A|青蒿素及其衍生物在抑制血小板衍生生长因子受体a中的作用及其应用

The invention relates to effects and application of artemisinin and its derivative in inhibition of platelet-derived growth factor receptor A. Particularly, artemisinin and its derivative directly act on a molecular target platelet-derived growth factor receptor A (PDGFR alpha) of a tumor and combines with PDGFR alpha on a cell membrane to inhibit activation of tyrosine kinase at the intracellular domain of PDGFR alpha, inhibit protein stability of PDGFR alpha, and promote a ubiquitin-dependent
Artemisinin Patent｜青蒿素专利

Application of the qinghaosu in the hepatoma Hep G 2 cells drug candidate of preparation treatment EMT activation|青蒿素在制备治疗EMT激活的肝癌HepG2细胞候选药物中的应用

The invention discloses a kind of applications in the hepatoma Hep G 2 cells drug candidate of preparation treatment EMT activation.Qinghaosu has extensive biology and pharmacological action, and wherein effective antitumour effect causes extensive concern in recent years.The mechanism that qinghaosu plays specific anticancer activity is still unclear, this may limit its further development in preclinical and clinical setting.It is inhibited to hepatocellular carcinoma H22 that the present inven
Artemisinin Patent｜青蒿素专利

A kind of combination product and its application for preventing and/or treating cerebral ischemia|一种用于预防和/或治疗脑缺血的组合产品及其应用

The invention belongs to biomedicine technical fields, specifically, being related to a kind of combination product and its application for preventing and/or treating cerebral ischemia.The combination product is the pharmaceutical composition containing Sur1 inhibitor and qinghaosu Sesquiterpene lactones compound；Or the combination for the first medicament containing Sur1 inhibitor and the second medicament containing qinghaosu Sesquiterpene lactones compound.Sur1 inhibitor and qinghaosu Sesquit
Artemisinin Patent｜青蒿素专利

Dihydroartemisinin derivative, medicine and application thereof in preparation of medicine for preventing and treating cerebrovascular diseases|一种双氢青蒿素衍生物、药物及其在制备治疗预防脑血管病药物中的应用

The invention provides a novel dihydroartemisinin derivative, which can be used as an active ingredient to prepare a medicine for preventing and treating ischemic cerebral apoplexy, and the medicine can pass through a blood brain barrier more easily and has higher brain tissue medicine concentration. 本发明提供了一种新的双氢青蒿素衍生物，以该双氢青蒿素衍生物为活性成分可制备成预防、治疗缺血性脑卒中的药物，而且所述药物更容易通过血脑屏障，具有更高的脑组织药物浓度。     Dihydroartemisinin der
Artemisinin Patent｜青蒿素专利

Method for increasing artemisinin content in sweet wormwood by DBR2 (double bond reductase 2) gene transfer|转dbr2基因提高青蒿中青蒿素含量的方法

The invention provides a method for increasing artemisinin content in sweet wormwood by DBR2 (double bond reductase 2) gene transfer in the field of biotechnology. The method includes the steps: cloning genes of artemisinic aldehyde delta 11(13) DBR2 from the sweet wormwood, constructing a plant expression vector containing the DBR2 genes, using agrobacterium tumefaciens for mediation to transfer the DBR2 genes into the sweet wormwood so that plants regenerate, using PCR (polymerase chain reacti
Artemisinin Patent｜青蒿素专利

A method of content of artemisinin in sweet wormwood is improved using AaSPL2 gene|一种利用AaSPL2基因提高青蒿中青蒿素含量的方法

A method of content of artemisinin in sweet wormwood is improved using AaSPL2 gene, include the following steps: to clone salicylic acid signal pathway AaSPL2 gene from sweet wormwood, construct the plant expression vector of the gene containing AaSPL2, with Agrobacterium tumefaciens mediated, AaSPL2 gene is transferred to sweet wormwood and regenerates plant, PCR detects the integration of external source target gene AaSPL2, then measures the content of qinghaosu in transgene abrotanum, and scr
Artemisinin Patent｜青蒿素专利

Biotechnological Approaches for Production of Artemisinin, an Anti-Malarial Drug from Artemisia annua L.

The article from MDPI discusses various biotechnological approaches to enhance the production of artemisinin, an important anti-malarial drug derived from the plant Artemisia annua. It covers the significance of artemisinin in malaria treatment and explores methods like tissue culture, genetic engineering, and bioreactor-based approaches to boost its yield. The review particularly focuses on the propagation of A. annua through cell and organ cultures, employing strategies like elicitation and me
Artemisinin Patent｜青蒿素专利

CN102048728A青蒿素衍生物在制备治疗克罗恩病的药物中的应用|Application of artemisinin derivative in preparation of medicaments for treating Crohn disease

The invention discloses an application of an artemisinin derivative in preparation of medicament for treating Crohn disease, and the artemisinin derivative is selected from artesunate or artemether or styrene monomer 905 (SM905). The artemisinin derivative can be used for achieving the purpose of treating the Crohn disease by inhibiting Th1/Th17 immune response and inhibiting nuclear factor-kB activation. Compared with the existing medicaments, the artemisinin derivative has less and light side
Artemisinin Patent｜青蒿素专利

CN101940569A含有索拉非尼和青蒿素及青蒿素类衍生物的药物组合物及其在制备治疗癌症的药物中的应用|Medicament composition containing sorafenib, artemisinin and artemisinin derivative and application thereof in preparing medicament for treating cancer

The invention relates to a medicament composition containing sorafenib, artemisinin and an artemisinin derivative and application thereof in preparing a medicament for treating lung cancer, pancreas cancer, colon cancer, liver cancer, prostatic cancer, kidney cancer, stomach cancer, brain tumor, sarcoma, ovarian cancer or breast cancer. The medicament composition has remarkable synergistic effect, improves the curative effect of the medicament, reduces the administration dosage and reduces side
Artemisinin Patent｜青蒿素专利

CN101879158A青蒿素衍生物的新应用---防治肥胖病的|New application of artemisinin derivant

The invention discloses an application of arteannuin derivant with the structure disclosed in I,II,III, IV and V for preparing medicines for preventing and treating adiposity, wherein n=0-1; R1 is selected from C1-C3 alkyl; and the R2 is selected from aryl or aromatic heterocyclic ring substituted by nitrogenous atom. The medicine prepared from the arteannuin organisms is taken as the medicine for resisting adipose differentiation and can play a very important role in treating the diseases.
Artemisinin Patent｜青蒿素专利

CN101773238B一种青蒿素的应用----制备方法以及作为杀菌剂和保鲜剂在果蔬保鲜利用和采后病害防治中的应用|

The invention discloses Artemisia apiacea extract and a preparation method and application thereof. The Artemisia apiacea extract is prepared by waste Artemisia apiacea residue discarded during the production of Artemisinin or directly by Artemisia apiacea plant, and has inhibiting effect on pathogenic bacteria of microbe diseases of picked fruits and vegetables and especially has obvious bacteria inhibition in vitro of picked fruit germs such as orange green mould, banana and mango anthracnose,
Artemisinin Patent｜青蒿素专利

CN101756957A含有青蒿素和青蒿素衍生物和抗生素|Combined application of artemisinin and its derivative and antibiotic medicine

The present invention discloses the new use of available antimalarial arteannuin and its derivatives dihydro arteannuin, antiannuic methyl ether, antiannuic ethyl ether and antiannuic amber. Arteannuin and its derivatives are used through combination with antibiotic medicine to inhibit bacterial growth and enhance the antibiotic effect of available antibiotic medicine. Especially, antiannuic amber is applied in preventing and treating bacterial infection diseases except being used as antimalaria
Artemisinin Patent｜青蒿素专利

青蒿叶粉囊的惊人功效｜The surprising efficiency of Artemisia annua powder capsules

Short link to this article: https://gettr.ink/X2catz   该研究评估了使用青蒿叶粉作为预防疟疾发作的治疗方法，在25名患者中进行了评估，其中大部分是儿童，所有患者都因骨科问题接受了手术治疗。治疗持续时间为36小时的患者有11例，60小时的患者有14例。平均寄生虫数量从432个/毫升降至165个/毫升，即改善了62％，而且根据治疗持续时间的不同没有显著差异。不论患者的年龄和体重如何，疗效都是相似的。这些结果是在非常低的粉末量（每天400至500毫克）和极低的青蒿素数量（每天0.4至0.5毫克）下获得的。结论是青蒿叶粉似乎比茶制品更有效，但成本更高，可能不易获得。廉价且随处可得的茶制品仍然是大规模预防和治疗疟疾的最佳方法，在最贫困的国家应优先选择使用。除了研究寨卡病毒感染外，术前调查还包括检测消化道寄生虫（所有病例均呈阳性）和艾滋病病毒检测（除了一个成年患者外，所有病例均呈阴性）。   表1 不同制备方法得到的[
Artemisinin Patent｜青蒿素专利

干叶青蒿素：发展中国家实用的疟疾治疗方法？｜Dried-leaf Artemisia annua: A practical malaria therapeutic for developing countries?

Short link to this article: https://gettr.ink/zPHa8E   来自植物青蒿（Artemisia annua L）的青蒿素，作为青蒿素联合疗法（ACT），是目前治疗疟疾的最佳疗法，这种疾病尤其在发展中国家影响儿童和成人。传统上，中国人将青蒿作为茶用于治疗“发热”。近年来的研究表明，青蒿茶浸提物和口服该植物的干叶具有预防和治疗效果。在青蒿叶中存在的复杂化学物质基质似乎增强了青蒿素的生物利用度和功效。尽管这些植物化学物质在抗疟疾活性方面约比青蒿素弱1000倍，但主要是包括其他青蒿素化合物、萜类化合物（主要是单萜和倍半萜）、类黄酮类和多酚酸的小分子。此外，青蒿叶的多糖成分可能增强了青蒿素的生物利用度。啮齿动物的药代动力学研究显示，在接受青蒿叶治疗的Plasmodium chabaudi感染小鼠中，T1/2和Tmax更长，Cmax和AUC更大，而在健康小鼠中则相对较小。在健康小鼠中，与纯青蒿素喂养的小鼠相比，接受干叶青蒿素的小鼠血清中青蒿素水
Artemisinin Patent｜青蒿素专利

CN1680388A青蒿素的提取方法｜Extraction of artemisine

本发明公开一种提取青蒿素的方法，包括采用60～70％的乙醇为溶剂浸提原料青蒿叶，还包括：1)沉淀：调节浸提液pH值到7.5～8.0，使大部分杂质沉淀，过滤并调节母液pH值6.5～7.0；2)减压浓缩：将母液浓缩至原体积的8～1 5％，冷却除杂；3)结晶：加等量70％乙醇加热至溶解，静置析出粗结晶；4)重结晶：用热石油醚溶解粗结晶，静置分离后，得到精品。本发明采用生石灰粉CaO作为沉淀剂，既沉淀了大部分杂质，又易于结晶的形成，同时降低了成本，并采用石油醚作为的重结晶溶剂，重结晶效果优于酒精，利用本发明得到青蒿素精品总收率大于0.4％。   青蒿素的提取方法 技术领域： 本发明涉及一种中药提取方法，特别涉及从菊科植物青蒿中提取青蒿素的方法。 背景技术： 青蒿素是我国科学家在1971年首次从菊科植物黄花蒿(Artemisiaannua Linn)提取出的具有新型结构的倍半萜内酯。纯青蒿素为无色针状晶体，熔点150～153℃，比旋光度[α]D 23+75°至+78°(无水乙醇)，味苦，易溶于苯、
Artemisinin Patent｜青蒿素专利

CN101569601A具有祛痘功能的组合物及其应用｜CN101569601A Compound with acne-removing function and its application

CN101569601A具有祛痘功能的组合物及其应用 CN101569601A Compound with acne-removing function and its application 具有祛痘功能的组合物及其应用 本发明公开了一种具有祛痘功能的组合物及其应用，该组合物按重量份计由下述组分组成：青蒿素母液1～10份、乳木果油5～100份；其能平衡油脂分泌，去除老化角质，疏通毛孔，杀菌消炎，并能促进细胞新陈代谢，修复受损肌肤，在祛痘的同时除印、平疤，长期使用可以有效抑制痤疮生成，还原健康肌肤，且安全无毒；以本发明组合物为活性成分，与一种或多种化妆品可接受的载体按照常规制备方法可以制成各种剂型的祛痘化妆品，满足广大痤疮患者的迫切需要，具有良好的应用前景；此外，本发明将青蒿素母液变废为宝，充分回收利用资源，可以提高经济效益和社会效益。   具有祛痘功
Artemisinin Patent｜青蒿素专利

CN101428034A增减毒抗肿瘤复方药物｜CN101428034A Compound medicine for increasing and decreasing toxicity and anti-tumor effect

CN101428034A增减毒抗肿瘤复方药物 CN101428034A Compound medicine for increasing and decreasing toxicity and anti-tumor effect   具有增效减毒特点的抗肿瘤组合药物 本发明涉及一种具有增效减毒效果的抗肿瘤组合药物，该组合药物是主要由替尼泊苷和青蒿素的衍生物组成的，这种组合药物由于在抑制特定肿瘤细胞生长时具有的增效减毒效果，适合于制备抗肿瘤药物，特别适合于制备治疗脑神经胶质瘤、肝癌、宫颈癌的药物。   具有增效减毒特点的抗肿瘤组合药物 技术领域 本发明涉及一种具有增效减毒特点的抗肿瘤组合药物，特别涉及到用于制备治疗脑神经胶质瘤、肝癌和宫颈癌的药物的抗肿瘤组合药物，属于抗癌药物技术领域。 背景技
Artemisinin Patent｜青蒿素专利

CN101282722A使用青蒿素及其衍生物治疗和预防良性色素痣（痣）---所述制剂对治疗痣细胞痣最适，对黑素细胞痣特别有效，从而也可用于预防皮肤癌｜CN101282722A Artemisinin and its derivatives for treating and preventing benign melanocytic nevi (moles) --- The preparation is most suitable for treating epidermal nevi, particula

CN101282722A使用青蒿素及其衍生物治疗和预防良性色素痣（痣）---所述制剂对治疗痣细胞痣最适，对黑素细胞痣特别有效，从而也可用于预防皮肤癌     用青蒿素及其衍生物治疗和预防良性色素斑（痣） 皮肤良性色素痣或脚癣或甲真菌病可用局部给药的、特别是式(I)的局部用配方活性成分来治疗，式中X代表CO、CHOZ或CHNRZ，Z选自氢、直链或支链(C1－C6)烷基、直链或支链(C2－C6)烯基、直链或支链(C2－C6)炔基、(C3－C8)环烷基、(C6－C24)芳基、(C7－C24)芳烷基、间－CH2(C6H4)COOM和对－CH2(C6H4)COOM；COR3；CSR3；C(NR6)R3；SOR4；SO2OM；SO2NR7R8；SO2O－蒿素基；SO2NH－蒿素基；POR4R5和PSR4R5；R3代表直链或支链(C1－C6)烷基、直链或支链(C1－C6)烷氧基；直链或支链(C2－C6)烯基；直链或支链(C2－C6)炔基；(C3－C8)环烷基；(C6－C24)芳基；(C6－C10)芳氧基；(C7－C24)芳烷
Artemisinin Patent｜青蒿素专利

CN101244027A治疗皮肤病的蒿甲醚经皮给药制剂---可用于多形性日光疹、 植物日光性皮炎、异位性皮炎及湿疹等皮肤疾病的治疗｜CN101244027A: Artemether Transdermal Administration Formulation for Treating Skin Diseases - Suitable for Treating Skin Diseases Such as Polymorphic Light Eruption, Phytophotodermatitis, At

CN101244027A治疗皮肤病的蒿甲醚经皮给药制剂---可用于多形性日光疹、 植物日光性皮炎、异位性皮炎及湿疹等皮肤疾病的治疗 CN101244027A: Artemether Transdermal Administration Formulation for Treating Skin Diseases - Suitable for Treating Skin Diseases Such as Polymorphic Light Eruption, Phytophotodermatitis, Atopic Dermatitis, and Eczema   治疗皮肤病的蒿甲醚经皮给药制剂 本发明涉及一种蒿甲醚的经皮给药制剂，由主药蒿甲醚、透皮吸收促进剂或透皮吸收载体及其他药用辅料组成。研究表明，抗疟药蒿甲醚作为一种新型的免疫调节剂可用于某些皮肤类疾病的治疗。本发明所述经皮给药制剂中的蒿甲醚可直接作用于患处皮肤表面，并能透过表皮进入真皮层及皮下组织，与蒿甲醚其他给药途径相比，可大大增加蒿甲醚在患处皮肤中的药量，以
Artemisinin Patent｜青蒿素专利

CN101223177A水溶性青蒿素衍生物｜CN101223177A: Water-Soluble Derivatives of Artemisinin

CN101223177A水溶性青蒿素衍生物 CN101223177A: Water-Soluble Derivatives of Artemisinin 水溶性青蒿素衍生物、制法、药物组合物及用途 本发明公开了一类水溶性青蒿素衍生物、制备方法、药物组合物及它的用途。该类衍生物的结构如右，经药理试验证明该类化合物及药物组合物具有明显的免疫抑制活性作用，可开发成为治疗人体免疫功能亢进引起的疾病(红斑狼疮、类风湿关节炎，多发性硬化症等自身免疫性疾病)，以及细胞器官移植后抗移植物排斥反应的新型免疫抑制药物。   PCT国内申请，说明书已公开。   Water-soluble arteannuin derivant, production method, medicine composition and
Artemisinin Patent｜青蒿素专利

CN101125142A青蒿素在制备抗肿瘤多药耐药药物中的应用｜CN101125142A: Application of Artemisinin in the Preparation of Anti-Tumor Multidrug-Resistant Drugs

CN101125142A青蒿素在制备抗肿瘤多药耐药药物中的应用 CN101125142A: Application of Artemisinin in the Preparation of Anti-Tumor Multidrug-Resistant Drugs   青蒿素在制备抗肿瘤多药耐药药物中的应用 本发明公开了青蒿素、二氢青蒿素、青蒿琥酯在制备抗肿瘤多药耐药药物中的应用，公开了青蒿素、二氢青蒿素、青蒿琥酯在制备作为长春新碱抗肿瘤增效剂药物中的应用，公开了青蒿素、二氢青蒿素、青蒿琥酯在制备治疗口腔鳞上皮癌药物中的应用，通过实验证实上述应用具有重要的临床意义。   青蒿素在制备抗肿瘤多药耐药药物中的应用 技术领域 本发明涉及青蒿素在制备抗肿瘤多药耐药药物中的应用，属于医药领域。 背景技术 肿瘤多药耐药是导致肿
×
×
  • Create New...

Important Information

Registration Terms & Conditions

  I accept